Abstract：Objective To explore the correlation between dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) multi-function histogram parameters (Ktrans, Kep, Ve) and the expression of programmed death ligand 1 (PD-L1) in triple-negative breast cancer. Methods A collection of 52 patients with triple-negative breast cancer who were pathologically confirmed in the Tangshan People’s Hospital, Hebei Province from December 2019 to June 2020. Before surgery or before puncture, DCE-MRI was performed to calculate the histogram parameters of the MRI multi-function parameters (Ktrans, Kep, Ve) of the patient’s lesions, and the positive expression of PD-L1 in each lesion was detected by immunohistochemistry. The expression of PD-L1 was detected by two scoring methods: tumor positive cell score (TPS) and immune cell score (IC). According to the expression of PD-L1, they were divided into negative group and positive group, and the significance of each histogram quantitative parameter and the positive expression of PD-L1 in breast cancer was evaluated. Results In the TPS scoring system for triple-negative breast cancer, the positive expression rate of PD-L1 was 21.15%, and in the IC scoring system, the positive expression rate of PD-L1 was 40.38%. In the IC score group, the mean Ktrans, Ktrans P50, and Ktrans P75 values of the PD-L1 positive group were higher than those of the negative group (P ＜ 0.05). The mean Kep, Kep P25, and Kep P50 values of the PD-L1 positive group were higher than those of the negative group (P ＜ 0.05). In the TPS scoring group, the PD-L1 scoring status was compared in various functional parameters of MRI, and the difference was not statistically significant (P ＞ 0.05). Conclusion In the IC score group, PD-L1 positive triple-negative breast cancer patients have higher Ktrans and Kep. Therefore, MRI multifunctional parameters may be an effective imaging index for pre-evaluating whether patients with triple-negative breast cancer can be immunotherapy.
李骥 彭飞 王硕. 增强MRI多功能直方图参数与三阴乳腺癌PD-L1表达的相关性分析[J]. 中国医药导报, 2021, 18(34): 30-34.
LI Ji PENG Fei WANG Shuo. Correlation between histogram analysis parameters derived from DCE-MRI and the expression of PD-L1 in triple-negative breast cancer#br#. 中国医药导报, 2021, 18(34): 30-34.
[1] Bianchini G，Balko JM，Mayer IA，et al. Triple-negative breast cancer：challenges and opportunities of a heterogeneous disease [J]. Nat Rev Clin Oncol，2016，13（11）：674-690.
[2] 陶海云，屈中玉，吴艳林，等.免疫治疗相关蛋白PD-1/PD-L1在三阴乳腺癌中的表达及临床意义[J].癌症进展，2019，17（2）：173-182.
[3] Brockhoff G，Seitz S，Weber F，et al. The presence of PD-1 positive tumor infiltrating lymphocytes in triple negative breast cancers is associated with a favorable outcome of disease [J]. Oncotarget，2017，9（5）：6201-6212.
[4] 张佳琪，贾红燕.PD-1/PD-L1抑制剂在乳腺癌中的研究进展[J].中国普外基础与临床杂志，2017，19（5）：409-413.
[5] Gillies RJ，Kinahan PE，Hricak H. Radiomics：images are more than pictures，they are data [J]. Radiology，2016，278（2）：563-577.
[6] 高雅，许永生，冯雯，等.动态增强MRI定量参数及其直方图在乳腺癌中的研究进展[J].中国介入影像与治疗学，2021，18（3）：183-186.
[7] Lehmann BD，Jovanovi■ B，Chen X，et al. Refinement of triple-negative breast cancer molecular subtypes：implications for neoadjuvant chemotherapy selection [J]. PLoS One，2016，11（6）：e0157368.
[8] Parvathareddy SK，Siraj AK，Ahmed SO，et al. PD-L1 Protein Expression in Middle Eastern Breast Cancer Predicts Favorable Outcome in Triple-Negative Breast Cancer [J]. Cells，2021，10（2）：229.
[9] Salgado R，Denkert C，Demaria S，et al. The evaluation of tumor-infiltrating lymphocytes （TILs） in breast cancer： recommendations by an International TILs Working Group 2014 [J]. Ann Oncol，2015，26（2）：259-271.
[10] Mittendorf EA，Philips AV，Meric-Bernstam F，et al. PD-L1 expression in triple-nagative breast cancer [J]. Cancer Immunol Res，2014，2（4）：361-370.
[11] 杨芳，陈晓品.PD-1/PD-L1在三阴乳腺癌中的研究进展[J].现代肿瘤医学，2017，25（15）：2511-2514.
[12] 金吕程，韩桂燕，董晓彤，等.PD-L1表达与CD8阳性T细胞在乳腺癌中相关性探讨[J].诊断病理学杂志，2020，27（12）：899-903.
[13] Schmid P，Adams S，Rugo HS，et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer [J]. N Engl J Med，2018，379（22）：2108-2121.
[14] Li K，Hongqi T. Development of small- molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy [J]. JDrug Target，2019，27（3）：244-256.
[15] 张艳珍，胡蝶，郑瑞，等.PD-1及其配体PD-L1与乳腺癌的研究进展[J].沈阳医学院学报，2021，23（2）：177-181.
[16] Khalifa F，Soliman A，El-Baz A，et al. Models and methods for analyzing DCE-MRI：a review [J]. Med Phys，2014， 41（12）：124301.
[17] 王洁，唐文伟，田忠甫，等.乳腺癌DCE-MRI参数及ADC与病理分子预后标记物的相关性分析[J].磁共振成像，2021，12（3）：76-79.
[18] 黄亚男，赵振华，毛海佳，等.不同病理类型肺癌磁共振定量灌注直方图参数、表观扩散系数与Ki-67相关性分析[J].中华医学杂志，2019，99（21）：1645-1650.
[19] Meyer HJ，Hhn AK，Surov A. Associations between histogram analysis parameters derived from dynamic contrast enhanced MRI and PD L1-expression in head and neck squamous cell carcinomas. A preliminary study [J]. Man Reson Imaging，2020，72，117-121.
[20] Li L，Kai W，Sun X，et al. Parameters of dynamic contrast-enhanced MRI as imaging markers for angiognersis and proliferation in human breast cancer [J]. Med Sci Monit，2015，21：376-382
[21] 尚海龙，杨玲，沈海林，等.3.0T MR多定量参数与乳腺癌预后因子Ki-67相关性研究[J].影像诊断与介入放射学，2017，26（5）：383-387.
[22] 范晓杰，王心然，岳萌，等.PD-L1在三阴乳腺癌组织中表达及其与脉管生成的关系[J].中国肿瘤生物治疗杂志，2019，26（11）：1229-1234.
[23] Stanton SE，Adams S，Disis ML. Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes：a systematic review [J]. JAMA Oncol，2016，2（10）：1354-1360.
[24] Ahn SG，Kim SK，Shepherd JH，et al. Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer [J]. Breast Cancer Res Treat，2021， 188（1）：165-178.
[25] 任殿泉，冯立文，乌仁高娃.PD-L1和miR-34a在三阴乳腺癌中的表达及相关性研究[J].诊断病理学杂志，2020，27（1）：38-41.
京公网安备 11010502046598号